Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.
November 26, 2025 | Intelligent Commercialisation, artificial intelligence
Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.
As health and life sciences companies prepare for launch, teams often face the same challenge: data lives in silos. Omnichannel engagement data, field insights, and clinical indicators sit in separate systems – making it difficult to form a connected view of readiness or identify the levers that will most influence launch success.
InConcert™ unites these fragmented datasets to help commercial and medical leaders answer the questions that matter most:
- Which HCPs are showing early interest or unmet need?
- Where are we under- or over-investing across channels?
- How is our field and MSL activity likely to impact uptake?
- What indicators point to the strongest early launch opportunities?
By combining proprietary and client-owned data into one intelligent suite, InConcert™ transforms uncertainty into foresight – helping teams model scenarios, anticipate challenges, and activate strategies with clarity and confidence.
The full picture of commercial performance
InConcert™ integrates omnichannel, field, and clinical behavior data through an LLM-powered interface that enables intuitive, natural-language querying.
Guided by embedded data scientists and cross-functional experts from across Inizio, users can interrogate their data in real time – moving seamlessly from insight to action.
“InConcert™ helps clients bring their data into focus – turning scattered signals into a clear view of launch readiness,” said Mary-Kate McGarry, Chief Strategy & Innovation Officer, Inizio.
“When teams can see where physicians are most responsive, how field activity drives uptake, and where investment will have the greatest impact, they can make every launch decision with greater insight and confidence.”
A connected intelligence solution built for the pivotal pre-launch moment
At this stage of the lifecycle, success depends on understanding how behavior, communication, and clinical context intersect. InConcert™ combines four core data layers that, together, provide an unparalleled pre-launch vantage point:
- Omnichannel intelligence: More than 25M hours of HCP engagement data reveal where interest is building, which messages resonate, and which needs remain unmet.
- Field performance insight: Over 200 brand meeting analyses uncover how in-field activity shapes perception and influence, informing targeting and deployment strategy.
- Clinical foresight: U.S. and EU modeling of real-world evidence connects clinical signals to commercial outcomes – helping teams understand where market readiness is strongest.
- Predictive engagement: AI-driven models trained on longitudinal datasets forecast behavioral shifts, guiding investment toward the highest-impact channels and content.
Together, these layers create a continuously learning system – one that adapts to each therapy area and market, giving teams a real-time view of where and how to act.
Leading the future of Intelligent Commercialization™ with InConcert™
By uniting three critical assets, InConcert™ positions Inizio at the forefront of Intelligent Commercialization™.
- Proprietary data and infrastructure: Decades of integrated datasets spanning engagement, scientific, and commercial domains.
- A connective AI backbone: A modular, LLM-powered platform that makes complex data easy to query, interpret, and operationalize.
- Embedded expertise: Access to specialists from across Inizio – whose insights are both built into the models and available on demand – ensuring every interpretation is grounded in scientific and strategic rigor.
Fast to activate and easy to scale, InConcert™ can be deployed within 10–14 weeks, with flexible pilot options that integrate quickly into existing systems and launch workflows.
“Every InConcert™ deployment starts with a client challenge,” said Jamie Avallone, Chief Data Officer, Inizio Evoke.
“Whether it’s identifying high-value targets or validating go-to-market assumptions, InConcert™ gives teams the answers they need – turning complex data into clear, confident launch decisions.”
With more than 700 pharma and biotech partnerships, Inizio helps clients unlock the full potential of their data – transforming fragmented insights into the connected intelligence that drives confident, high-impact launches.
Learn more about InConcert™ or get in touch with one of our experts today.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?
In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy...
Webcast: Understanding the Chronic Disease Patient Journey in Emerging Markets
In emerging markets where primary care systems do not exist, the patient is the only constant in the journey
PEGASUS JOINS ASHFIELD HEALTHCARE COMMUNICATIONS
Pegasus, one of the most successful integrated healthcare communications consultancies in the UK, has today announced it has been acquired by UDG Healthcare plc, a FTSE 250 listed international provider...
Living with Crohn’s Report
Are you looking for a deeper understanding of the emotional needs, behaviours and treatment programmes of patients living with Crohn’s Disease?
Infographic: Research Partnership
Our latest infographic offers an overview of some key facts and figures about the company, its services and capabilities.
AAD conference 2016
Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients
Video: Global Biosimilars Market
Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch
Case study: Understanding Patient Willingness to Pay in Emerging Markets
Our client wanted to identify the optimum selling price for their chronic disease treatment in emerging markets, based on patient’s willingness to pay for the product out of pocket.Find out...
From promise to practice: immuno-oncology in action Part 3 – Emerging Markets
Our latest white paper on immuno-oncology explores the challenges and opportunities in emerging markets, with a focus on Asia.
It’s a digital hat trick for Pegasus as it scoops GOLD and two SILVERS at the PM Society Digital Awards 2016
Pegasus received three top accolades at the PM Society Digital Media Awards 2016, including gold for the highly acclaimed Craft: Best Innovation award with Biogen’s MS Explorer, and two silvers...